Cargando…

Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline

BACKGROUND: While substantial progress has been made in the development of disease-modifying medications for multiple sclerosis (MS), a high percentage of treated patients still show progression and persistent inflammatory activity. Autologous haematopoietic stem cell transplantation (AHSCT) aims at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bayas, Antonios, Berthele, Achim, Blank, Norbert, Dreger, Peter, Faissner, Simon, Friese, Manuel A., Gerdes, Lisa-Ann, Grauer, Oliver Martin, Häussler, Vivien, Heesen, Christoph, Janson, Dietlinde, Korporal-Kuhnke, Mirjam, Kowarik, Markus, Kröger, Nikolaus, Lünemann, Jan D., Martin, Roland, Meier, Uwe, Meuth, Sven, Muraro, Paolo, Platten, Michael, Schirmer, Lucas, Stürner, Klarissa Hanja, Stellmann, Jan Patrick, Scheid, Christof, Bergh, Florian Then, Warnke, Clemens, Wildemann, Brigitte, Ziemssen, Tjalf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540601/ https://www.ncbi.nlm.nih.gov/pubmed/37780055 http://dx.doi.org/10.1177/17562864231180730

Ejemplares similares

Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?
por: Stellmann, Jan-Patrick, et al.
Publicado: (2015)

Is multiple sclerosis progression associated with the HLA-DR15 haplotype?
por: Stürner, Klarissa Hanja, et al.
Publicado: (2019)

Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders
por: Bayas, A., et al.
Publicado: (2021)

Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis
por: Stürner, Klarissa Hanja, et al.
Publicado: (2020)

Reliability of cortical lesion detection on double inversion recovery MRI applying the MAGNIMS-Criteria in multiple sclerosis patients within a 16-months period
por: Faizy, Tobias Djamsched, et al.
Publicado: (2017)

Correction: Increased Perfusion in Normal Appearing White Matter in High Inflammatory Multiple Sclerosis Patients
por: Bester, Maxim, et al.
Publicado: (2015)

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
por: Haas, Jürgen, et al.
Publicado: (2019)

Heterogeneity of multiple sclerosis lesions in fast diffusional kurtosis imaging
por: Thaler, Christian, et al.
Publicado: (2021)

Clinical associations and characteristics of the polyspecific intrathecal immune response in elderly patients with non-multiple sclerosis chronic autoimmune-inflammatory neurological diseases – a retrospective cross-sectional study
por: Brauchle, Felix, et al.
Publicado: (2023)

Development of Cortical Lesion Volumes on Double Inversion Recovery MRI in Patients With Relapse-Onset Multiple Sclerosis
por: Faizy, Tobias D., et al.
Publicado: (2019)

Turning When Using Smartphone in Persons With and Those Without Neurologic Conditions: Observational Study
por: Bianchini, Edoardo, et al.
Publicado: (2023)

B-cell-depletion reverses dysbiosis of the microbiome in multiple sclerosis patients
por: Troci, Alba, et al.
Publicado: (2022)

A case of CLIPPERS syndrome responsive to tocilizumab
por: Rempe, Torge, et al.
Publicado: (2019)

Association of obesity with disease outcome in multiple sclerosis
por: Lutfullin, Isabel, et al.
Publicado: (2023)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Stammzelltransplantation bei Multipler Sklerose - wo stehen wir?
por: Heesen, Christoph, et al.
Publicado: (2022)

B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis
por: Schwarz, Alexander, et al.
Publicado: (2016)

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
por: Häußler, Vivien, et al.
Publicado: (2021)

Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring
por: Stoessel, Daniel, et al.
Publicado: (2018)

Antibody-mediated cell depletion therapies in multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Assessing the effect of an evidence-based patient online educational tool for people with multiple sclerosis called UMIMS—understanding magnetic resonance imaging in multiple sclerosis: study protocol for a double-blind, randomized controlled trial
por: Schiffmann, Insa, et al.
Publicado: (2020)

The importance of collecting structured clinical information on multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Treating sarcoidosis-associated progressive multifocal leukoencephalopathy with infliximab
por: Rosenkranz, Sina C., et al.
Publicado: (2021)

Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis – a review of population-specific evidence from randomized clinical trials
por: Bayas, Antonios, et al.
Publicado: (2023)

Comprehensive Implementation of Shared Decision Making in a Neuromedical Center Using the SHARE TO CARE Program
por: Stolz-Klingenberg, Constanze, et al.
Publicado: (2023)

Validating Predictors of Disease Progression in a Large Cohort of Primary-Progressive Multiple Sclerosis Based on a Systematic Literature Review
por: Stellmann, Jan-Patrick, et al.
Publicado: (2014)

Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab
por: Kowarik, Markus C., et al.
Publicado: (2016)

Smartphone Accelerometry: A Smart and Reliable Measurement of Real-Life Physical Activity in Multiple Sclerosis and Healthy Individuals
por: Zhai, Yuyang, et al.
Publicado: (2020)

Quantification and Proximal-to-Distal Distribution Pattern of Tibial Nerve Lesions in Relapsing-Remitting Multiple Sclerosis: Assessment by MR Neurography
por: Pietsch, Adriana M., et al.
Publicado: (2022)

Impairment and restrictions in possibly benign multiple sclerosis
por: Schaefer, Laura Melanie, et al.
Publicado: (2019)

Ocular outcome and frequency of neurological manifestations in patients with acute posterior multifocal placoid pigment epitheliopathy (APMPPE)
por: Thomas, Bettina C., et al.
Publicado: (2012)

Innovation in Digital Education: Lessons Learned from the Multiple Sclerosis Management Master’s Program
por: Voigt, Isabel, et al.
Publicado: (2021)

T1w dark blood imaging improves detection of contrast enhancing lesions in multiple sclerosis
por: Thaler, Christian, et al.
Publicado: (2017)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System—A Review
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice
por: Beste, Christian, et al.
Publicado: (2020)

Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

T1 Relaxation Times in the Cortex and Thalamus Are Associated With Working Memory and Information Processing Speed in Patients With Multiple Sclerosis
por: Thaler, Christian, et al.
Publicado: (2021)

Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
por: Jarius, Sven, et al.
Publicado: (2023)

Driving time-based identification of gaps in specialised care coverage: An example of neuroinflammatory diseases in Germany
por: Masanneck, Lars, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8hl1ctu58iv2j2faedrm2j6j4i